African genomics startup 54gene raises $25M to expand precision medicine capabilities –

▤ Summary

With the world’s analyzed genomes coming mostly from anywhere that isn’t Africa, the continent remains a valuable source of new genetic information for health and drug discovery research. Last year when we covered the company, CEO Ene-Obong disclosed that for 54gene to conduct this research, it recruits voluntary participants who donate genetic samples via swab or blood tests. However, instead of depending on third-party health centres like hospitals and sending the samples abroad for analysis, 54gene launched its own genetics sequencing and microarray lab in Lagos last September. “Though the arc of conducting early research through drug approval can be long in biotech, we have taken the approach to building the backbone that is needed for short-term successes to long-term gains that provide better healthcare delivery and treatment outcomes from diseases,” he added. 54gene made some hires to this end: Michelle Ephraim, Colm O’Dushlaine, Peter Fekkes, Teresia Bost and Jude Uzonwanne — all of whom have decades of experience working with companies like Leica Biosystems, Regeneron Genetic Center, Novartis, Celgene and the Bill and Melinda Gates Foundation.

$ Funding

▦ Linked Companies

Illumina

$1B+